{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:41:45Z","timestamp":1774428105217,"version":"3.50.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81860225"],"award-info":[{"award-number":["81860225"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013064","name":"Key Research and Development Program of Jiangxi Province","doi-asserted-by":"publisher","award":["20203BBG73060"],"award-info":[{"award-number":["20203BBG73060"]}],"id":[{"id":"10.13039\/501100013064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20212BAB206029"],"award-info":[{"award-number":["20212BAB206029"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020205","name":"Health Commission of Jiangxi Province","doi-asserted-by":"publisher","award":["20195116"],"award-info":[{"award-number":["20195116"]}],"id":[{"id":"10.13039\/501100020205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Three dopamine agonists [bromocriptine, cabergoline, and quinagolide (CV)] have been used for hyperprolactinemia treatment for decades. Several studies have reviewed the efficacy and safety of bromocriptine and cabergoline. However, no systematic review or meta-analysis has discussed the efficacy and safety of CV in hyperprolactinemia and prolactinoma treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Five medical databases (PubMed, Web of Science, Embase, Scopus, and Cochrane Library) were searched up to 9 May 2022 to identify studies related to CV and hyperprolactinemia. A meta-analysis was implemented by using a forest plot, funnel plot, sensitivity analysis, meta-regression, and Egger\u2019s test <jats:italic>via<\/jats:italic> software R 4.0 and STATA 12.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1,211 studies were retrieved from the five medical databases, and 33 studies consisting of 827 patients were finally included in the analysis. The pooled proportions of patients with prolactin concentration normalization and tumor reduction (&amp;gt;50%) under CV treatment were 69% and 20%, respectively, with 95% confidence intervals of 61%\u201376% and 15%\u201328%, respectively. The pooled proportion of adverse effects was 13%, with a 95% confidence interval of 11%\u201316%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study showed that CV is not less effective than cabergoline and bromocriptine in treating hyperprolactinemia, and the side effects were not significant. Hence, this drug could be considered an alternative first-line or rescue treatment in treating hyperprolactinemia in the future.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:uri>, identifier CRD42022347750.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1027905","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T07:36:38Z","timestamp":1674545798000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Yanyang","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingliang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunzhi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiacong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI20401","article-title":"Mechanisms for pituitary tumorigenesis: The plastic pituitary","volume":"112","author":"Melmed","year":"2003","journal-title":"J Clin Invest"},{"key":"B2","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: The old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-64-5-1021","article-title":"Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea","volume":"64","author":"Schlechte","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: Systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","article-title":"Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: A systematic review and meta-analysis","volume":"59","author":"Xia","year":"2018","journal-title":"Endocrine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0708-3","article-title":"Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when","volume":"19","author":"Dogansen","year":"2016","journal-title":"Pituitary"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-014-0617-2","article-title":"Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: A systematic review and meta-analysis","volume":"18","author":"Hu","year":"2015","journal-title":"Pituitary"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-72-5-1136","article-title":"The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine","volume":"72","author":"van der Lely","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-008-9107-z","article-title":"Medical therapy of pituitary adenomas: Effects on tumor shrinkage","volume":"10","author":"Colao","year":"2009","journal-title":"Rev Endocr Metab Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0912025","article-title":"Clinical practice. prolactinomas","volume":"362","author":"Klibanski","year":"2010","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012884214668","article-title":"Quinagolide in the management of prolactinoma","volume":"3","author":"Schultz","year":"2000","journal-title":"Pituitary"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.01016.X","article-title":"Efficacy of quinagolide in resistance to dopamine agonists: Results of a multicenter study. club de l'Hypophyse","volume":"61","author":"Rohmer","year":"2000","journal-title":"Ann Endocrinol (Paris)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.8.5001","article-title":"Prolactinomas in children and adolescents. clinical presentation and long-term follow-up","volume":"83","author":"Colao","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1350548","article-title":"Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males","volume":"135","author":"Colao","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1350413","article-title":"Prolactinomas resistant to bromocriptine: Long-term efficacy of quinagolide and outcome of pregnancy","volume":"135","author":"Morange","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000182496","article-title":"Prolactinomas and resistance to dopamine agonists","volume":"38","author":"Brue","year":"1992","journal-title":"Horm Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.74.3.1346788","article-title":"Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine","volume":"74","author":"Brue","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3109\/09513599409072452","article-title":"Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine","volume":"8","author":"Merola","year":"1994","journal-title":"Gynecol Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/0753-3322(94)90105-8","article-title":"CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states","volume":"48","author":"Merola","year":"1994","journal-title":"BioMed Pharmacother"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb02799.x","article-title":"Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine","volume":"41","author":"Vilar","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1280301","article-title":"Long-term treatment of macroprolactinomas with CV 205-502","volume":"128","author":"Kvistborg","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347910","article-title":"CV 205-502 treatment of macroprolactinomas","volume":"14","author":"Crottaz","year":"1991","journal-title":"J Endocrinol Invest"},{"key":"B24","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1055\/s-2008-1063739","article-title":"Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502","volume":"81","author":"Barnett","year":"1991","journal-title":"Q J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb01731.x","article-title":"Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas","volume":"34","author":"Duranteau","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)54175-2","article-title":"CV 205-502\u2013effectiveness, tolerability, and safety over 24-month study","volume":"55","author":"Shoham","year":"1991","journal-title":"Fertil Steril"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1250170","article-title":"Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502","volume":"125","author":"Rasmussen","year":"1991","journal-title":"Acta Endocrinol (Copenh)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-9-668","article-title":"Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502","volume":"112","author":"Vance","year":"1990","journal-title":"Ann Intern Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-71-3-682","article-title":"Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas","volume":"71","author":"Serri","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1990.tb03900.x","article-title":"Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502","volume":"33","author":"van't Verlaat","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-71-2-354","article-title":"Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas","volume":"71","author":"Khalfallah","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)60966-4","article-title":"The effectiveness, safety, and tolerability of CV 205-502 in hyperprolactinemic women: A 12-month study","volume":"52","author":"van der Heijden","year":"1989","journal-title":"Fertil Steril"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-68-2-336","article-title":"CV 205-502 treatment of hyperprolactinemia","volume":"68","author":"Vance","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1988.tb01225.x","article-title":"Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinaemia","volume":"29","author":"Rasmussen","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/BF03343751","article-title":"A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients","volume":"23","author":"De Luis","year":"2000","journal-title":"J Endocrinol Invest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","article-title":"The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas","volume":"53","author":"Di Sarno","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.00951.x","article-title":"Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: Predictive value of pituitary scintigraphy with 123I-methoxybenzamide","volume":"52","author":"Colao","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1159\/000184630","article-title":"Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas","volume":"44","author":"Colao","year":"1995","journal-title":"Horm Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/BF03344963","article-title":"A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients","volume":"17","author":"Giusti","year":"1994","journal-title":"J Endocrinol Invest"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)55201-7","article-title":"The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia","volume":"58","author":"Lappohn","year":"1992","journal-title":"Fertil Steril"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/0028-2243(91)90101-p","article-title":"CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia","volume":"40","author":"van der Heijden","year":"1991","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1250385","article-title":"Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: A double-blind study","volume":"125","author":"Verhelst","year":"1991","journal-title":"Acta Endocrinol (Copenh)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1990.tb00899.x","article-title":"A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia","volume":"32","author":"Homburg","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01071","article-title":"A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with cabergoline","volume":"104","author":"Stiles","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S1575-0922(09)72711-1","article-title":"[Cabergoline in hyperprolactinemia and valvular heart disease]","volume":"56","author":"Vargas","year":"2009","journal-title":"Endocrinol Nutr"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345662","article-title":"Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: A meta-analysis from clinical studies","volume":"31","author":"Bogazzi","year":"2008","journal-title":"J Endocrinol Invest"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1027905\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T07:36:45Z","timestamp":1674545805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1027905\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":46,"alternative-id":["10.3389\/fendo.2023.1027905"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1027905","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"article-number":"1027905"}}